biotech · Breast Cancer · Advanced Breast Cancer · PBYI
PUMA BIOTECHNOLOGY
PUMA BIOTECHNOLOGY, INC.
PUMA BIOTECHNOLOGY clinical programs — 28 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 10880 Wilshire Blvd, Los Angeles, CA 90024, US
- Founded
- 2010
- Employees
- 257
- Programs
- 40
- Drugs
- 23
- Patents
- 1
PUMA BIOTECHNOLOGY projects
28 ClinicalTrials.gov programs sponsored by PUMA BIOTECHNOLOGY.
PUMA BIOTECHNOLOGY has 28 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Alisertib
PUMA BIOTECHNOLOGY, INC.
Small Cell Lung Cancer ( SCLC )
1 trial -
Alisertib
PUMA BIOTECHNOLOGY, INC.
Hormone Receptor Positive HER-2 Negative Breast Cancer
1 trial -
Alisertib
PUMA BIOTECHNOLOGY, INC.
Small Cell Lung Cancer
1 trial -
Capecitabine
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
1 trial -
HKI-272
PUMA BIOTECHNOLOGY, INC.
Advanced Breast Cancer
2 trials -
HKI-272
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
1 trial -
HKI-272
PUMA BIOTECHNOLOGY, INC.
Carcinoma, Non-Small-Cell Lung
1 trial -
NERATINIB
PUMA BIOTECHNOLOGY, INC.
Stage IV (Metastatic) Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
HER2 Amplified Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Advanced Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Anatomic Stage I Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
8 trials -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Early-stage Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Early Stage HER2+ Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
GastroEsophageal Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
HER2-positive Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Metastatic Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Metastatic Prostate Adenocarcinoma
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Solid Tumor, Adult
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Triple Negative Breast Cancer
1 trial -
PUMA-ALI-1201
PUMA BIOTECHNOLOGY, INC.
Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)
1 trial -
Paclitaxel
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
1 trial -
Temozolomide
PUMA BIOTECHNOLOGY, INC.
Glioblastoma
1 trial -
Temsirolimus
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
1 trial -
Trastuzumab
PUMA BIOTECHNOLOGY, INC.
Metastatic Colorectal Cancer
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
Breast Neoplasms
3 trials -
neratinib
PUMA BIOTECHNOLOGY, INC.
HER2-mutant Non-Small Cell Lung Cancer
1 trial
Frequently asked questions
How many clinical projects does PUMA BIOTECHNOLOGY have?
28 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.